Tyr75

Site Information
RsINGELyAPLQHVs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3957211

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	liver cancer ( 1 , 3 , 4 ) , cholangiocellular carcinoma ( 1 ) , hepatocellular carcinoma ( 4 )
Relevant cell line - cell type - tissue:	hepatocyte-liver ( 4 ) , Jurkat (T lymphocyte) ( 2 ) , liver ( 1 , 3 )

References
1	Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640 21253578 Curated Info
2	Possemato A (2010) CST Curation Set: 9703; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	Gu T (2010) CST Curation Set: 9475; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
4	Gu T (2009) CST Curation Set: 7522; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info